Drug Profile
Research programme: eye disorder therapies - Handok Pharmaceuticals
Alternative Names: HL 5501; HL 5511; HL5521Latest Information Update: 24 May 2019
Price :
$50
*
At a glance
- Originator Handok Inc
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Diabetic macular oedema; Glaucoma
Most Recent Events
- 24 May 2019 Discontinued for Age-related macular degeneration in South Korea (unspecified route) (Handok pipeline, May 2019)
- 24 May 2019 Discontinued for Diabetic macular oedema in South Korea (unspecified route) (Handok pipeline, May 2019)
- 24 May 2019 Discontinued for Glaucoma in South Korea (unspecified route) (Handok pipeline, May 2019)